Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Murray

Showing results (71-80 of 122) with videos related to

Pageof 13
Sort By:
American Journal of Hematology|August 15, 2018
MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptomsTaxiarchis Kourelis, David L Murray, Surendra Dasari, et al.
Radiology|May 9, 2018
Accumulation of Gadolinium in Human Cerebrospinal Fluid after Gadobutrol-enhanced MR Imaging: A Prospective Observational Cohort StudyAvinash K Nehra, Robert J McDonald, Amy M Bluhm, et al.
Human Pathology|March 22, 2016
Giant cell interstitial pneumonia in patients without hard metal exposure: analysis of 3 cases and review of the literatureAndras Khoor, Anja C Roden, Thomas V Colby, et al.
Diagnostic Pathology|August 5, 2022
Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphomaVandana Baloda, Sarah E Wheeler, David L Murray, et al.
Clinical Chemistry|August 8, 2019
Correlation Between Kappa Prozone Effect and IgA Kappa M Proteins in Serum Free Light-Chain AssayKatherine A Turner, Laura L Eckelkamp, Stephanie J Kalass, et al.
Diagnostic Pathology|October 21, 2022
Correction: Mu heavy chain disease with MYD88 L265P mutation: An unusual manifestation of lymphoplasmacytic lymphomaVandana Baloda, Sarah E Wheeler, David L Murray, et al.
Clinical Chemistry|August 29, 2024
Comparison of 2 Free Light Chain Assays: Performance of the Free Light Chain Ratio as a Risk Factor for MGUS ProgressionQian Wang, Benjamin D Andress, Vanessa M K Pazdernik, et al.
Clinical Chemistry|August 20, 2016
Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass SpectrometryJohn R Mills, Mindy C Kohlhagen, Surendra Dasari, et al.
Mayo Clinic Proceedings|December 10, 2021
Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 CasesSurendra Dasari, Mindy C Kohlhagen, Angela Dispenzieri, et al.
Blood Cancer Journal|February 10, 2021
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee ReportDavid L Murray, Noemi Puig, Sigurdur Kristinsson, et al.
Pageof 13

Showing results (71-80 of 122) with videos related to

Sort By:
Pageof 13
American Journal of Hematology|August 15, 2018
MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptomsTaxiarchis Kourelis, David L Murray, Surendra Dasari, et al.
Radiology|May 9, 2018
Accumulation of Gadolinium in Human Cerebrospinal Fluid after Gadobutrol-enhanced MR Imaging: A Prospective Observational Cohort StudyAvinash K Nehra, Robert J McDonald, Amy M Bluhm, et al.
Human Pathology|March 22, 2016
Giant cell interstitial pneumonia in patients without hard metal exposure: analysis of 3 cases and review of the literatureAndras Khoor, Anja C Roden, Thomas V Colby, et al.
Diagnostic Pathology|August 5, 2022
Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphomaVandana Baloda, Sarah E Wheeler, David L Murray, et al.
Clinical Chemistry|August 8, 2019
Correlation Between Kappa Prozone Effect and IgA Kappa M Proteins in Serum Free Light-Chain AssayKatherine A Turner, Laura L Eckelkamp, Stephanie J Kalass, et al.
Diagnostic Pathology|October 21, 2022
Correction: Mu heavy chain disease with MYD88 L265P mutation: An unusual manifestation of lymphoplasmacytic lymphomaVandana Baloda, Sarah E Wheeler, David L Murray, et al.
Clinical Chemistry|August 29, 2024
Comparison of 2 Free Light Chain Assays: Performance of the Free Light Chain Ratio as a Risk Factor for MGUS ProgressionQian Wang, Benjamin D Andress, Vanessa M K Pazdernik, et al.
Clinical Chemistry|August 20, 2016
Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass SpectrometryJohn R Mills, Mindy C Kohlhagen, Surendra Dasari, et al.
Mayo Clinic Proceedings|December 10, 2021
Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 CasesSurendra Dasari, Mindy C Kohlhagen, Angela Dispenzieri, et al.
Blood Cancer Journal|February 10, 2021
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee ReportDavid L Murray, Noemi Puig, Sigurdur Kristinsson, et al.
Pageof 13